Held by 4 specialist biotech funds
High Convergence**Signal Note: Avoro Capital Iniciates $307M Position in APLS** Avoro's substantial entry signals conviction in Apellis' complement-targeting pipeline, likely anchored on pegcetacoplan's commercial ramp in paroxysmal nocturnal hemoglobinuria (PNH) and expanding label potential in C3 glomerulopathy following recent clinical readouts.
AI analyst context — unlock full analysis
# Signal Note: OrbiMed Initiates $61M Position in Apellis OrbiMed's new 2.4M share stake in Apellis likely reflects conviction in pegcetacoplan's commercial trajectory following recent regulatory wins in geographic atrophy (AMD) and C3 glomerulopathy, two high-unmet-need indications with limited competition. The timing suggests confidence in near-term revenue ramp and cash flow inflection as the company executes on a narrower, more focused pipeline post-restructuring. Watch for upcoming peak sales guidance revisions and gross margin expansion as key catalysts validating this thesis.
+ 2more — see how much conviction went in
See the Full Story